Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab for inflammatory and idiopathic choroidal neovascular membranes
2008-007476-19Phase 3Completed
- Sponsor
- University Hospitals Bristol and Weston NHS Foundation Trust
- Start
- Sep 2009
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ranibizumab in Subretinal neovascularization and idiopathic choroidal neovascularization (ICNV), sponsored by University Hospitals Bristol and Weston NHS Foundation Trust. Primary endpoints: Proportion of subjects gaining 15 or more ETDRS letters at 12 months and Likelihood of moderate loss of vision. Started Sep 2009; status: completed.
02
Drugs
ranibizumab
03
Conditions
Subretinal neovascularizationidiopathic choroidal neovascularization (ICNV)
Beyond the preview
Go deeper on 2008-007476-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007476-19.